[161-Tb]PB-TT012

N/A

Report date: 2025/11/24 17:31:44

NME

Base Information

Drug Name[161-Tb]PB-TT012

Drug Alias Name[161-Tb]PB-TT012

ClassificationRadiation-emitting products > Radioactive therapeutic agentSmall molecules > Heterocyclic drugsRadiation-emitting products > Nuclides > Terbium > 161Tb +[4]

Mechanisms of ActionProstate-Specific Membrane Antigen inhibitors

TargetsProstate-Specific Membrane Antigen

Therapy Area/IndicationsColorectal Neoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryTaiwan

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesPrimo Biotechnology Co Ltd

China Registration ClassN/A

Develop Information

Active CompaniesPrimo Biotechnology Co Ltd

Inactive CompaniesN/A

Active IndicationsColorectal Neoplasms

Inactive IndicationsN/A

Other Information

ATC CodeN/A